688315 Stock Overview
Provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Novogene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.54 |
| 52 Week High | CN¥21.22 |
| 52 Week Low | CN¥9.03 |
| Beta | 0.82 |
| 1 Month Change | -4.28% |
| 3 Month Change | 17.83% |
| 1 Year Change | -5.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688315 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 3.6% | 2.3% | 0.6% |
| 1Y | -5.3% | 11.2% | 4.1% |
Return vs Industry: 688315 underperformed the CN Life Sciences industry which returned 11.2% over the past year.
Return vs Market: 688315 underperformed the CN Market which returned 4.1% over the past year.
Price Volatility
| 688315 volatility | |
|---|---|
| 688315 Average Weekly Movement | 11.2% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 10.5% |
| 10% least volatile stocks in CN Market | 4.4% |
Stable Share Price: 688315's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688315's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,202 | Ruiqiang Li | www.novogene.com |
Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcriptome, isoform, direct RNA, prokaryotic RNA, and metatranscriptome sequencing; and single cell gene expression, single cell long road read transcriptome, and visium formalin-fixed paraffin-embedded spatial transcriptome solutions. It also provides epigenomic solutions comprising whole genome bisulfite, reduced representation bisulfite, chromatin immunoprecipitation, and RNA immunoprecipitation sequencing; premade library and proteomics services; clinical diagnostics services, such as clinical whole exome sequencing and clinical panels; biopharma services consisting of discovery and pre-clinical, translational and clinical, and companion diagnostics; and support services.
Novogene Co., Ltd. Fundamentals Summary
| 688315 fundamental statistics | |
|---|---|
| Market cap | CN¥5.89b |
| Earnings (TTM) | CN¥203.35m |
| Revenue (TTM) | CN¥2.14b |
29.0x
P/E Ratio2.7x
P/S RatioIs 688315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688315 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.14b |
| Cost of Revenue | CN¥1.22b |
| Gross Profit | CN¥925.81m |
| Other Expenses | CN¥722.46m |
| Earnings | CN¥203.35m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 43.16% |
| Net Profit Margin | 9.48% |
| Debt/Equity Ratio | 1.2% |
How did 688315 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 01:16 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novogene Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |